Zacks Research Upgrades Progyny (NASDAQ:PGNY) to “Strong-Buy”

Progyny (NASDAQ:PGNY) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other research analysts have also weighed in on PGNY. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 price objective for the company in a research note on Tuesday, January 20th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 target price on shares of Progyny in a research report on Friday, March 6th. Finally, Canaccord Genuity Group cut their target price on Progyny from $26.00 to $19.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.91.

Progyny Trading Up 23.8%

Shares of Progyny stock opened at $23.72 on Thursday. The company has a market capitalization of $1.86 billion, a P/E ratio of 30.81, a price-to-earnings-growth ratio of 1.10 and a beta of 0.91. The stock has a fifty day simple moving average of $17.87 and a 200 day simple moving average of $21.69. Progyny has a 12-month low of $16.10 and a 12-month high of $28.75.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.03. The business had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a return on equity of 12.76% and a net margin of 5.23%.The business’s revenue was down 26.4% on a year-over-year basis. During the same period last year, the business earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. On average, analysts predict that Progyny will post 1.12 EPS for the current year.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 7,455 shares of company stock valued at $129,515 in the last quarter. 9.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. raised its holdings in Progyny by 57.1% during the 3rd quarter. Principal Financial Group Inc. now owns 704,267 shares of the company’s stock valued at $15,156,000 after acquiring an additional 256,078 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Progyny by 2.4% in the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after acquiring an additional 235,513 shares during the period. Algert Global LLC boosted its holdings in shares of Progyny by 35.1% in the third quarter. Algert Global LLC now owns 595,805 shares of the company’s stock worth $12,822,000 after acquiring an additional 154,930 shares during the period. Intech Investment Management LLC grew its position in shares of Progyny by 336.0% in the third quarter. Intech Investment Management LLC now owns 169,834 shares of the company’s stock valued at $3,655,000 after purchasing an additional 130,885 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Progyny by 79.2% during the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock valued at $33,904,000 after purchasing an additional 696,447 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

More Progyny News

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny beat Q1 estimates, reporting $0.50 adjusted EPS versus $0.44 expected and revenue of $328.5 million versus $326.5 million forecast, helping reinforce the stock’s move higher. Progyny, Inc. Announces First Quarter 2026 Results
• Positive Sentiment: The company raised second-quarter and full-year 2026 guidance, with Q2 EPS outlook of $0.50 to $0.53 and FY2026 EPS guidance of $1.98 to $2.09, both above Wall Street estimates, which supports confidence in future earnings power. Conference call and earnings materials
• Positive Sentiment: Management said early selling-season activity and member engagement were strong, and the company highlighted continued share repurchases, with 8.8 million shares bought back since November, adding another supportive signal for investors. Progyny, Inc. Announces First Quarter 2026 Results
• Neutral Sentiment: Revenue was still down 26.4% year over year, so while the quarter beat expectations, investors may remain focused on whether growth can stabilize after the recent decline. Progyny: Q1 Earnings Snapshot
• Neutral Sentiment: Some commentary noted concern around flat revenue guidance, which could temper the bullish reaction if investors want clearer top-line acceleration going forward. The Bull Case For Progyny (PGNY) Could Change Following Flat Q1 2026 Revenue Guidance Concerns

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.